Literature DB >> 23294157

Diagnostic nomenclature for foetal alcohol spectrum disorders: the continuing challenge of causality.

A R Miller1.   

Abstract

Prenatal alcohol exposure is a risk factor for neurologically based cognitive and adaptive disability. Diagnostic nomenclature for prenatally exposed children with cognitive and adaptive disability who lack features for foetal alcohol syndrome (FAS) or partial FAS includes the terms alcohol-related neurodevelopmental disorder (ARND) and foetal alcohol spectrum disorder(s) (FASD). Although these terms are now widely used, this paper argues that both are problematic. ARND is flawed by unjustifiably turning a risk factor into a causal factor and shrouding the result in terminological ambiguity, while FASD is not appropriate as a clinical label, and its use as a proxy for ARND deflects critical attention from the causal inferencing that is integral to diagnosing children with an alcohol-related teratogenic condition. Existing nomenclature is at odds with logical and evidence-based diagnosing and also has implications for interpretation of epidemiological data. Diagnostic nomenclature that is not tightly linked to causal inference is preferable at the present stage of this field's development.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  alcohol-related neurodevelopmental disorder; causality; foetal alcohol spectrum disorder(s); prenatal alcohol exposure; teratogenesis

Mesh:

Year:  2013        PMID: 23294157     DOI: 10.1111/cch.12017

Source DB:  PubMed          Journal:  Child Care Health Dev        ISSN: 0305-1862            Impact factor:   2.508


  1 in total

1.  Ethical aspects of diagnosis and interventions for children with fetal alcohol Spectrum disorder (FASD) and their families.

Authors:  Gert Helgesson; Göran Bertilsson; Helena Domeij; Gunilla Fahlström; Emelie Heintz; Anders Hjern; Christina Nehlin Gordh; Viviann Nordin; Jenny Rangmar; Ann-Margret Rydell; Viveka Sundelin Wahlsten; Monica Hultcrantz
Journal:  BMC Med Ethics       Date:  2018-01-05       Impact factor: 2.652

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.